+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong



Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong



American Journal of Cardiovascular Drugs 8(3): 199-205



In Hong Kong, about 10% of adults 25-74 years of age have diabetes mellitus. The management of dyslipidemia with lipid-lowering agents (LLAs), including HMG-CoA reductase inhibitors (statins) for the primary prevention of cardiovascular complications, has been found to be beneficial. This study examined statin utilization patterns for the primary prevention of cardiovascular events in patients with diabetes mellitus in two public hospitals in Kong Kong; clinical outcomes in patients who received statins for primary prevention were compared with those in patients not treated with any LLAs. This was a retrospective study in patients who were diagnosed with diabetes mellitus. Only patients with no prior history of coronary artery disease were included in the study. Utilization patterns of LLAs and the incidences of cardiovascular complications were recorded from 1 January 2002 to 31 December 2003. A total of 222 patient records were reviewed. Only 75/222 (33.8%) of patients with diabetes mellitus received one or more LLAs for the primary prevention of cardiovascular events. Among these patients, only 21% of patients attained target lipid goals. Nearly half of the patients who were not treated with LLAs (n=147) had dyslipidemia problems. The overall incidence of cardiovascular complications in patients treated and not treated with LLAs was 12.2%. Absence of routine screening for cardiovascular risk and sub-optimal utilization and inadequate dosage titration of LLAs were identified as contributory factors towards cardiovascular events in this patient group. The current study failed to prove the benefits of LLAs in reducing the risk of first cardiovascular events in diabetic patients. This may have been due to the use of low doses of LLAs and a lack of laboratory monitoring of cholesterol levels. Development and implementation of guidelines may help promote the use of LLAs in primary prevention of cardiovascular complications.

(PDF emailed within 1 workday: $29.90)

Accession: 055911523

Download citation: RISBibTeXText

PMID: 18533740


Related references

Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clinical Cardiology 35(12): 722-729, 2013

Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus. Diabetes and Metabolism Journal 38(1): 32-34, 2014

3rd World Congress on Prevention of Diabetes and its Complications held in conjunction with the 4th Hong Kong Diabetes and Cardiovascular Risk Factors - East Meets West Symposium, Hong Kong, China, September 29-October 1, 2002. Diabetes Research & Clinical Practice 57(Supplement 1): S1-S43, 2002

3rd World Congress on Prevention of Diabetes and its Complications (WPCD) held in conjunction with the 4th Hong Kong Diabetes and Cardiovascular Risk Factors - East Meets West (EmW) Symposium, Hong Kong, China, September 29-October 1, 2002. Diabetes Research and Clinical Practice 57(Supplement 1): S1-S43, 2002

Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. Bmc Cardiovascular Disorders 17(1): 166, 2018

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8(): 21-21, 2007

Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs 65(1): 137-152, 2004

Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events. Nederlands Tijdschrift Voor Geneeskunde 153: A109, 2009

A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. European Review for Medical and Pharmacological Sciences 23(5): 2302-2310, 2019

Should a statin be routinely prescribed for primary prevention of cardiovascular disease in diabetes mellitus?. Canadian Medical Association Journal 171(8): 857-857, 2004

Statin Therapy: Diabetes Mellitus Risk and Cardiovascular Benefit in Primary Prevention. Israel Medical Association Journal 20(8): 480-485, 2018

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. Bmj 362: K3359, 2018

Ten-year risk prediction models of complications and mortality of Chinese patients with diabetes mellitus in primary care in Hong Kong: a study protocol. Bmj Open 8(10): E023070, 2018

The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community-based population study in Hong Kong Chinese. Hong Kong Cardiovascular Risk Factor Steering Committee. American Diabetes Association. Diabetic Medicine 17(10): 741-745, 2000

Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong: a community with high prevalence of Type 2 diabetes mellitus and impaired glucose tolerance. Diabetic Medicine 17(11): 798-806, 2000